SRCM
BIOTW

Sage Rock Capital Management’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

Sage Rock Capital Management’s Portfolio BIOTW Stock Details BIOTW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-286,900
Closed -$69K – 359
2022
Q1 		$69K Hold
286,900
– – 0.01% 214
2021
Q4 		$189K Hold
286,900
– – 0.03% 213
2021
Q3 		$189K Buy
+286,900
New +$213K 0.03% 182

Other funds holding BIOTW

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.78% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
RA
Ramius Advisors New York $95.2M AUM 7.33% 1-Year Est. Return
CCP
Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
KCM
Kingstown Capital Management New York $30.4M AUM 3.71% 1-Year Est. Return
QGA
Q Global Advisors Fort Worth, Texas $113M AUM 20.91% 1-Year Est. Return

Sage Rock Capital Management's BIOTW Position: Q2 2022 in Review

Sage Rock Capital Management sold out of Biotech Acquisition Company Warrant (BIOTW) in Q2 2022, closing a stake of 286,900 shares — an estimated $69K sold.

Sage Rock Capital Management first reported a position in BIOTW in Q3 2021 and held it in 3 quarters. The position peaked at $189K in Q4 2021. 48 funds tracked by Wall St. Rank hold BIOTW as of Q2 2022.

  • Sage Rock Capital Management reported no remaining Biotech Acquisition Company Warrant position as of Q2 2022 after selling out during the quarter.
  • Sage Rock Capital Management sold 286,900 Biotech Acquisition Company Warrant shares in Q2 2022, an estimated $69K.
  • Sage Rock Capital Management first reported a position in Biotech Acquisition Company Warrant in Q3 2021 and held it in 3 quarters.
  • Sage Rock Capital Management's Biotech Acquisition Company Warrant position peaked at $189K in Q4 2021.
  • 48 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q2 2022.

Based on Sage Rock Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.